lazcluze news - Search News

CNBC on MSN · 2d

J&J says its lung cancer drug combination keeps people alive longer

Johnson & Johnson said a combination of its lung cancer drugs Rybrevant and Lazcluze kept people alive for at least a year longer than AstraZeneca's Tagrisso in a clinical trial. J&J is trying to supplant AstraZeneca's blockbuster Tagrisso,

J&J says cancer drug combination showed survival benefit over Tagrisso

Results from the Mariposa study found a regimen of Rybrevant and Lazcluze helped patients with a common form of advanced lung cancer live longer.

Becker's Hospital Review · 1d

Drug extends survival in lung cancer patients: J&J

Johnson & Johnson released results from a phase 3 study, showing that the combination of Rybrevant and Lazcluze significantly improved overall survival in patients with advanced non-small cell lung cancer that has specific epidermal growth factor receptor mutations.

Johnson & Johnson says its lung cancer drug significantly extended survival

Johnson & Johnson says its bispecific antibody, paired with a Janssen drug, could change treatment for non-small lung cancer patients.

MarketWatch · 2d

Johnson & Johnson Drug Combination Shows Positive Results in Lung Cancer Study

Johnson & Johnson said it received positive topline results in a Phase 3 study of a combination of drugs to treat patients with locally advanced or metastatic non-small cell lung cancer.

Rybrevant Plus Lazcluze Improves Survival for EGFR+ NSCLC

First-line Rybrevant plus Lazcluze improved survival versus the current standard of care in patients with mutated advanced or ...

With key win over AstraZeneca's Tagrisso, J&J touts Rybrevant-Lazcluze combo as 'new standard of care'

Johnson & Johnson’s combination of Rybrevant and Lazcluze has racked up an overall survival (OS) victory against ...

GlobalData on MSN1d

J&J reports positive topline outcomes from Phase III NSCLC combo therapy trial

Johnson & Johnson (J&J) has reported positive topline outcomes from the Phase III MARIPOSA trial of Rybrevant ...

2d

Johnson & Johnson’s rybrevant plus lazcluze improve survival in lung cancer

Johnson & Johnson announced positive topline results for the gold standard endpoint in cancer treatment of overall survival, or OS, from ...

The Pharma Letter1d

J&J combo surpasses Tagrisso in Phase III lung cancer test

Johnson & Johnson's Rybrevant and Lazcluze combination shows significant overall survival benefits over Tagrisso in the ...

EC approves Rybrevant with Lazcluze for advanced lung cancer

Janssen-Cilag International NV, a Johnson & Johnson company, announced that the European Commission has approved Rybrevant ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results